Search
TAK-875
Indications:
- investigational therapy for diabetes mellitus type 2
Mechanism of action:
- agonist of free fatty acid receptor 1 (FFAR1)
- stimulates insulin secretion with rising plasma glucose
Interactions
drug adverse effects of hypoglycemic agents
General
hypoglycemic agent
References
- Burant CF et al
TAK-875 versus placebo or glimepiride in type 2 diabetes
mellitus: a phase 2, randomised, double-blind, placebo-
controlled trial
The Lancet, Early Online Publication, 27 February 2012
PMID: 22374408
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61879-5/fulltext
- Bailey CJ
Could FFAR1 assist insulin secretion in type 2 diabetes?
The Lancet, Early Online Publication, 27 February 2012
PMID: 22374407
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60165-2/fulltext